BBS-Bioactive Bone Substitutes Plc, Company announcement, management transactions, 7 August 2023 at 16.00 (EEST)
BBS-Bioactive Bone Substitutes Oyj – Managers’ Transactions – Ahti Paananen
This Company announcement contains information on the following management transactions:
____________________________________________
Person subject to the notification requirement
Name: Paananen Ahti
Position: Member of the Board/Deputy member
Issuer: BBS Bioactive Bone Substitutes Oyj
LEI: 743700BYSBP0PCR6N767
Notification type: INITIAL NOTIFICATION
Reference number: 743700BYSBP0PCR6N767_20230803192300_8
____________________________________________
Transaction date: 2022-12-05
Venue not applicable
Instrument type: SHARE
ISIN: FI4000260583
Nature of the transaction: SUBSCRIPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 20,836 Unit price: 0.92 EUR
Aggregated transactions
(1): Volume: 20,836 Volume weighted average price: 0.92 EUR
Contact information:
Ilkka Kangasniemi, CEO
040 708 0307
ilkka.kangasniemi@bbs-artebone.fi
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…